Q1 2022 HTG Molecular Diagnostics Inc Earnings Call Transcript
Thank you for standing by. This is the conference operator. Welcome to the HTG Molecular Diagnostics, Inc. First Quarter 2022 Earnings Call. As a reminder, the conference is being recorded. (Operator Instructions)
I would now like to turn the conference over to Ms. Monique Kosse with LifeSci Advisors. Please go ahead.
Thank you, operator. Before we begin the call, let me remind you that the company's remarks include forward-looking statements within the meaning of the federal securities laws, including statements regarding our expected revenue build and momentum in 2022, our expectations regarding profiling revenue in future periods, our expectation that customers may use our HTP and whole transcriptome miRNA panel for their studies as a result of the harmonized sample preparation protocol, the importance of the company's HTG transcriptome panel statements related to the company's HTG Therapeutics and Drug Discovery business, the impacts of recent hires, our planned white paper for specific drug discovery
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |